Guardant Health (GH) Reports Q1 Loss, Tops Revenue Estimates
Yahoo Finance · 4 hours ago
Open | 18.36 |
High | 19.50 |
Low | 18.01 |
Mkt Cap | 2.37B |
P/E (TTM) | N/A |
Div & Yield | N/A & N/A |
Prev. Close | 18.64 |
52 Wk. Low | 15.81 |
52 Wk. High | 41.06 |
Related stocks
Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally.
Guardant Health is an American biotechnology company based in Palo Alto, California. Co-founders Helmy Eltoukhy and AmirAli Talasaz serve as co-chief executive officers. Wikipedia
(USD) | Q4 2023 | Y/Y |
---|---|---|
Revenue | 155.05M | 22.20% ▲ |
Net Income | -187.04M | - |
Diluted EPS | -1.58 | - |
Quarter | EPS Estimate | EPS Actual |
---|---|---|
Q1 2024 | -$0.85 | - |
Q4 2023 | -$0.86 | -$1.58 |
Q3 2023 | -$0.94 | -$0.73 |
S&P FuturesES=F | 5,242.00+3.00 (+0.06%) |
Dow FuturesYM=F | 39,572.00+36.00 (+0.09%) |
Nasdaq FuturesNQ=F | 18,221.00+6.50 (+0.04%) |
4.7500-1.25% | |
18.01+13.13% | |
30.42-22.06% |